The effect of irradiation on the biodistribution of radiolabeled pegylated liposomes

International Journal of Radiation Oncology Biology Physics

Volumn 50, Issue 3, 2001, Pages 809-820

  Harrington, Kevin J ^a,c   Rowlinson Busza, Gail ^a   Syrigos, Konstantinos N ^a   Uster, Paul S ^d   Vile, Richard G ^c   Peters, A Michael ^b   Stewart, J Simon W ^e  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c MAYO CLINIC   (United States)

^d ALZA CORPORATION   (United States)

^e CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Biodistribution; Pegylated liposome; Radiosensitizer; Radiotherapy

Indexed keywords

LIPOSOMES; RADIOSENSITIZERS;

BIOLOGICAL ORGANS; IRRADIATION; NEUROLOGY; RADIOTHERAPY; SKIN; TUMORS;

ONCOLOGY;

LIPOSOME; MACROGOL DERIVATIVE; PENTETATE INDIUM IN 111; TUMOR NECROSIS FACTOR ALPHA;

ADRENAL GLAND; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; FEMALE GENITAL SYSTEM; HEART; KIDNEY; LIVER; LUNG; MOUSE; MUSCULOSKELETAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOSENSITIZATION; SKIN; SMALL INTESTINE; SPLEEN WEIGHT; STOMACH; TUMOR; WHOLE BODY RADIATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; INDIUM RADIOISOTOPES; KB CELLS; LIPOSOMES; MALE; MICE; MICE, NUDE; PENTETIC ACID; POLYETHYLENE GLYCOLS; RADIOPHARMACEUTICALS; TIME FACTORS; TISSUE DISTRIBUTION; WHOLE-BODY IRRADIATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035400305     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01508-5     Document Type: Article

References (40)

1. Diffusion of univalent ions across the lamellae of swollen phospholipids
2. Liposomes revisited
3. Sterically stabilized liposomes; improvements in pharmacokinetics and antitumor therapeutic efficacy
4. Amphipathic polyethyleneglycols effectively prolong the circulation times of liposomes
5. Liposomes as vehicles for targeted therapy of cancer. ; Part 1: Preclinical development
6. A phase II study of STEALTH® pegylated liposomal doxorubicin (Doxil®, Caelyx®) and radiotherapy in the treatment of advanced head and neck squamous cell carcinoma (HNSCC) (Abstr.)
7. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer
8. Radiation enhancement of radiolabelled antibody deposition in tumors
9. Enhancement of monoclonal antibody binding to melanoma with single dose radiation or hyperthermia
10. Enhancement of monoclonal antibody uptake in human colon tumor xenografts following irradiation
11. 111In-DTPA-labeled pegylated liposomes
12. Propagation in a fluid medium of a human epidermoid carcinoma, strain KB
13. 111In-DTPA-labelled pegylated liposomes in a human tumor xenograft model; Implications for novel targetting strategies
14. 111In-DTPA-labelled pegylated liposomes in a human tumor xenograft model
15. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer
16. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma; Three meta-analyses of updated individual data
17. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
18. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy, and radiotherapy for locally advanced non-small-cell carcinoma of the lung
19. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma; Results of a North Central Cancer Treatment Group Phase III Study
20. Chemoradiotherapy of locally advanced esophageal cancer; Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group
21. Epidermoid anal cancer; results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UK Co-ordinating Committee on Cancer Research
22. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation, and adjuvant hysterectomy for bulky stage IB cervical carcinoma
23. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
24. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer
25. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder; A prospective study
26. Bladder preservation by combined modality therapy for invasive bladder cancer
27. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma
28. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region; Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group
29. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma
30. Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic astrocytoma and glioblastoma multiforme
31. Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study
32. Tumour-imaging potential of liposomes loaded with In-111-NTA. biodistribution in mice
33. Selective in vivo localisation of daunorubicin small unilamellar vesicles in solid tumours
34. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumour tissue
35. Liposome formulations with prolonged circulation time in blood and enhanced uptake in tumours
36. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumours; Biodistribution and imaging studies
37. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
38. Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma
39. Doxorubicin encapsulated in sterically stabilised liposomes for the treatment of a brain tumour model; Biodistribution and therapeutic efficacy
40. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas-Rationale for combination with radiotherapy